Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Int J Cancer. 2013 Mar 16;133(3):624–636. doi: 10.1002/ijc.28070

Figure 2.

Figure 2

Tumor cells treated with a chemotherapeutic agent undergo immunogenic modulation and demonstrate significantly increased sensitivity to antigen-specific CTL killing. (A) Human tumor cells were treated in vitro for 72 h with 2.5, 25, or 250 ng/mL of docetaxel, or left untreated. Cells were analyzed after each treatment for surface expression Fas, ICAM-1, CEA, MUC-1, MHC-I, and CRT. Numbers indicate percentage of positive cells. Numbers in parentheses denote MFI. Bold type indicates marked upregulation (≥ 10% increase in percent of cells or 30% increase in MFI not observed in isotype control vs. untreated cells). (B) Human tumor cells treated in vitro for 72 h with 25 (white bars) or 250 (black bars) ng/ml of docetaxel, or left untreated (gray bars), were used as targets in an 18-h CTL lysis assay. CEA-, PSA-, or MUC-1-specific CD8+ T cells were used as effector cells at an E:T ratio of 30:1. For controls, tumor cells were incubated with anti-HLA-A2 mAb or concanamycin A (CMA). CEA+HLA-A2− LS174T cells were used to verify CTL specificity. ND; not determined. * = statistical significance relative to untreated cells. This experiment was repeated 4 times with similar results.